Shelli R Mcalpine

List of Publications by Year
in descending order

75 papers	1,940 citations	236925 25 h-index	289244 40 g-index
76 all docs	76 docs citations	76 times ranked	2136 citing authors

#	Article	IF	Citations
1	Hsp90 Mediates Membrane Deformation and Exosome Release. Molecular Cell, 2018, 71, 689-702.e9.	9.7	103
2	Mechanistic Studies of Sansalvamide A-Amide: An Allosteric Modulator of Hsp90. ACS Medicinal Chemistry Letters, 2010, 1, 4-8.	2.8	97
3	Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development. Chemistry - A European Journal, 2021, 27, 1487-1513.	3.3	91
4	Design and synthesis of Hsp90 inhibitors: Exploring the SAR of Sansalvamide A derivatives. Bioorganic and Medicinal Chemistry, 2010, 18, 6822-6856.	3.0	73
5	Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1923-1928.	2.2	73
6	Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds. Tetrahedron, 2012, 68, 1029-1051.	1.9	71
7	Macrocycles That Inhibit the Binding between Heat Shock Protein 90 and TPR-Containing Proteins. ACS Chemical Biology, 2011, 6, 1357-1366.	3.4	68
8	Halting metastasis through CXCR4 inhibition. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 20-25.	2.2	62
9	Comprehensive Study of Sansalvamide A Derivatives and their Structureâ€“Activity Relationships against Drug-Resistant Colon Cancer Cell Lines. Journal of Medicinal Chemistry, 2008, 51, 530-544.	6.4	55
10	A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 661-666.	2.2	54
11	Nuclear factor ÎºBâ€“inducing kinase activation as a mechanism of pancreatic Î² cell failure in obesity. Journal of Experimental Medicine, 2015, 212, 1239-1254.	8.5	52
12	A comprehensive study of Sansalvamide A derivatives: The structureâ€“activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorganic and Medicinal Chemistry, 2009, 17, 5806-5825.	3.0	43
13	Synthesis of Second-Generation Sansalvamide A Derivatives: Novel Templates as Potential Antitumor Agents. Journal of Organic Chemistry, 2007, 72, 1980-2002.	3.2	41
14	Chemically Accessible Hsp90 Inhibitor That Does Not Induce a Heat Shock Response. ACS Medicinal Chemistry Letters, 2014, 5, 771-776.	2.8	40
15	Macrocyclic Inhibitors of Hsp90. Current Topics in Medicinal Chemistry, 2010, 10, 1380-1402.	2.1	39
16	Total Synthesis of trans,trans-Sanguinamide B and Conformational Isomers. Organic Letters, 2012, 14, 1198-1201.	4.6	39
17	Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4716-4719.	2.2	36
18	Synthesis and Cytotoxicity of Novel Sansalvamide A Derivatives. Organic Letters, 2005, 7, 3481-3484.	4.6	34

#	Article	IF	Citations
19	Synthesis of Sansalvamide A derivatives and their cytotoxicity in the MSS colon cancer cell line HT-29. Bioorganic and Medicinal Chemistry, 2006, 14, 5625-5631.	3.0	33
20	Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5072-5077.	2.2	32
21	Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors. Chemistry - A European Journal, 2017, 23, 2010-2013.	3.3	31
22	Improving the Cell Permeability of Polar Cyclic Peptides by Replacing Residues with Alkylated Amino Acids, Asparagines, and <scp>d</scp>-Amino Acids. Organic Letters, 2018, 20, 506-509.	4.6	31
23	Hydrothermal synthesis of highly luminescent blue-emitting ZnSe(S) quantum dots exhibiting low toxicity. Materials Science and Engineering C, 2016, 64, 167-172.	7.3	30
24	A potential rhodium cancer therapy: Studies of a cytotoxic organorhodium(I) complex that binds DNA. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2527-2531.	2.2	29
25	High-yielding macrocyclization conditions used in the synthesis of novel Sansalvamide A derivatives. Tetrahedron Letters, 2006, 47, 515-517.	1.4	26
26	Synthesis and novel structureâ€“activity relationships of potent sansalvamide A derivatives. Chemical Communications, 2006, , 1033.	4.1	25
27	Effectively Delivering a Unique Hsp90 Inhibitor Using Star Polymers. ACS Medicinal Chemistry Letters, 2013, 4, 915-920.	2.8	25
28	Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70. Organic and Biomolecular Chemistry, 2015, 13, 2108-2116.	2.8	25
29	C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1Î± through the Oxygen-Dependent Degradation Pathway. Cellular Physiology and Biochemistry, 2019, 53, 480-495.	1.6	25
30	Synthesis, Structureâ€“Activity Analysis, and Biological Evaluation of Sanguinamide B Analogues. Journal of Organic Chemistry, 2012, 77, 10596-10616.	3.2	24
31	C-terminal heat shock protein 90 modulators produce desirable oncogenic properties. Organic and Biomolecular Chemistry, 2015, 13, 4627-4631.	2.8	24
32	Scaffold Targeting Drug-Resistant Colon Cancers. Journal of Medicinal Chemistry, 2007, 50, 1999-2002.	6.4	23
33	Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics?. Future Medicinal Chemistry, 2015, 7, 87-90.	2.3	23
34	A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. Prostate, 2016, 76, 1546-1559.	2.3	23
35	Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2549-2554.	2.2	21
36	Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3409-3414.	2.2	21

#	Article	IF	Citations
37	Evaluation of Di-Sansalvamide A Derivatives: Synthesis, Structureâ^'Activity Relationship, and Mechanism of Action. Journal of Medicinal Chemistry, 2009, 52, 7927-7930.	6.4	20
38	Synthesis and Structureâ€"Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90. ACS Medicinal Chemistry Letters, 2018, 9, 73-77.	2.8	20
39	Nanoparticles for Bioapplications: Study of the Cytotoxicity of Water Dispersible CdSe(S) and CdSe(S)/ZnO Quantum Dots. Nanomaterials, 2019, 9, 465.	4.1	20
40	Total Synthesis and Biological Activity of Natural Product Urukthapelstatin A. Organic Letters, 2013, 15, 3574-3577.	4.6	18
41	Synthesis and Cytotoxicity of a New Class of Potent Decapeptide Macrocycles. Organic Letters, 2008, 10, 177-180.	4.6	17
42	Solid Phase versus Solution Phase Synthesis of Heterocyclic Macrocycles. Molecules, 2013, 18, 1111-1121.	3.8	17
43	Proteinâ€"protein inhibitor designed de novo to target the MEEVD region on the C-terminus of Hsp90 and block co-chaperone activity. Chemical Communications, 2019, 55, 846-849.	4.1	17
44	How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?. ChemMedChem, 2017, 12, 353-357.	3.2	16
45	Real time monitoring of peptide deliveryin vitrousing high payload pH responsive nanogels. Polymer Chemistry, 2020, 11, 425-432.	3.9	16
46	Predicting the unpredictable: Recent structureâ€"activity studies on peptide-based macrocycles. Bioorganic Chemistry, 2015, 60, 74-97.	4.1	15
47	A small molecule that preferentially binds the closed conformation of Hsp90. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7068-7071.	2.2	14
48	An Hsp90 modulator that exhibits a unique mechanistic profile. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3287-3290.	2.2	14
49	Hitting a Moving Target: How Does an Nâ€Methyl Group Impact Biological Activity?. ChemMedChem, 2016, 11, 881-892.	3.2	14
50	Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts. Organic and Biomolecular Chemistry, 2015, 13, 6299-6312.	2.8	13
51	Design, synthesis and anticancer mechanistic studies of linked azoles. MedChemComm, 2015, 6, 300-305.	3.4	13
52	A structureâ€"activity relationship study on multi-heterocyclic molecules: two linked thiazoles are required for cytotoxic activity. MedChemComm, 2013, 4, 406-410.	3.4	12
53	Histone deacetylase inhibitors: synthesis of cyclic tetrapeptides and their triazole analogs. Tetrahedron Letters, 2010, 51, 4357-4360.	1.4	11
54	Progress toward the synthesis of Urukthapelstatin A and two analogues. Tetrahedron Letters, 2012, 53, 4065-4069.	1.4	11

#	Article	IF	Citations
55	Sanguinamide B analogs: identification of active macrocyclic structures. Tetrahedron Letters, 2014, 55, 2389-2393.	1.4	11
56	Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (hsp90) inhibition: a significant advance on current hsp90 chemotherapies. RSC Advances, 2015, 5, 59003-59013.	3.6	11
57	Designing de Novo Small Molecules That Control Heat Shock Protein 70 (Hsp70) and Heat Shock Organizing Protein (HOP) within the Chaperone Protein-Folding Machinery. Journal of Medicinal Chemistry, 2019, 62, 742-761.	6.4	11
58	Synthesis of the Natural Product Marthiapeptide A. Organic Letters, 2015, 17, 5149-5151.	4.6	10
59	The fungal natural product (1S,3S)-austrocortirubin induces DNA damage in HCT116 cells via a mechanism unique from other DNA damaging agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 249-253.	2.2	10
60	Reinventing Hsp90 Inhibitors: Blocking Câ€Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors. Chemistry - A European Journal, 2016, 22, 18572-18582.	3.3	9
61	Dimerization of a heat shock protein 90 inhibitor enhances inhibitory activity. Organic and Biomolecular Chemistry, 2014, 12, 765-773.	2.8	8
62	RITA Mimics: Synthesis and Mechanistic Evaluation of Asymmetric Linked Trithiazoles. ACS Medicinal Chemistry Letters, 2017, 8, 401-406.	2.8	8
63	Mechanistic Studies of Sanguinamide B Derivatives: A Unique Inhibitor of Eukaryotic Ribosomes. Organic Letters, 2013, 15, 4638-4641.	4.6	7
64	Synthesis of macrocycles that inhibit protein synthesis: stereochemistry and structural based studies on sanguinamide B derivatives. Tetrahedron Letters, 2014, 55, 6979-6982.	1.4	6
65	Converting polar cyclic peptides into membrane permeable molecules using Nâ€methylation. Peptide Science, 2018, 110, e24063.	1.8	6
66	Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype. Chemical Communications, 2019, 55, 4515-4518.	4.1	5
67	Using NMR to identify binding regions for N and C-terminal Hsp90 inhibitors using Hsp90 domains. RSC Medicinal Chemistry, 2021, 12, 410-415.	3.9	4
68	Delivering bioactive cyclic peptides that target Hsp90 as prodrugs. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 728-739.	5.2	3
69	De Novo Design, Synthesis, and Mechanistic Evaluation of Short Peptides That Mimic Heat Shock Protein 27 Activity. ACS Medicinal Chemistry Letters, 2021, 12, 713-719.	2.8	3
70	Heat Shock Protein 27: Structure, Function, Cellular Role and Inhibitors. Topics in Medicinal Chemistry, 2015, , 221-234.	0.8	2
71	Targeting the C-Terminus of Hsp90 as a Cancer Therapy. Topics in Medicinal Chemistry, 2015, , 1-20.	0.8	2
72	Evaluating Dual Hsp90 and Hsp70 Inhibition as a Cancer Therapy. Topics in Medicinal Chemistry, 2015, , 55-80.	0.8	1

#	Article	IF	Citations
73	Functionalization of Quinazolinâ€4â€ones Part 3: Synthesis, Structures Elucidation, DNAâ€PK, PI3K, and Cytotoxicity of Novel 8â€Arylâ€2â€morpholinoâ€quinazolinâ€4â€ones. Journal of Heterocyclic Chemistry, 2019, 56, 124-141.	2.6	1
74	Delivering hydrophilic peptide inhibitors of heat shock protein 70 into cancer cells. Bioorganic Chemistry, 2022, 122, 105713.	4.1	1
75	Frontispiece: Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development. Chemistry - A European Journal, 2021, 27, .	3.3	0